| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6119578 | Journal of Clinical Virology | 2016 | 6 Pages |
Abstract
Achievement of SVR determines an important beneficial impact in terms of liver-related mortality and fibrosis regression, but does not seem to alter neither the slope of long term CD4 gain nor the CD4/CD8 ratio evolution in ART-treated HIV-HCV co-infected patients.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
A. Saracino, G. Bruno, L. Scudeller, N. Ladisa, N. de Gennaro, M. Allegrini, L. Monno, G. Angarano,